Abstract
Studies show that PD-L1 receptor expression is an independent survival prognosticator in gastric cancer patients. However, sparce real-world data exist on PD-L1 expression and decisions regarding treatment in gastric cancer. The objectives of this study were to assess PD-L1 expression and use of immune checkpoint inhibitor (ICI) therapies among gastric cancer patients in the U.S.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
